NATURES SUNSHINE PRODUCTS INC NATR
We are a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. We are a Utah corporation formed in 1976 with our principal place of business in Lehi, Utah. We sell our products to a sales force of independent consultants who use the products themselves or resell them to consumers.
We have four business segments (Asia, Europe, North America and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. The geographic segments operate under the Nature's Sunshine Products and Synergy WorldWide® brands. The Latin America and Other segment includes our wholesale business in which we sell products to various locally-managed entities, independent of the Company, that we have granted distribution rights for the relevant market.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $480.1M | $454.4M | $445.3M | $421.9M | $444.1M | $385.2M | $362.2M | $364.8M | $342.0M | $341.2M |
| Cost of revenue | $132.4M | $129.7M | $124.2M | $122.2M | $115.5M | $101.3M | $93.9M | $95.7M | $91.0M | $90.9M |
| Gross profit | $347.7M | $324.7M | $321.1M | $299.8M | $328.6M | $283.9M | $268.3M | $269.1M | $251.0M | $250.2M |
| R&D | $1.9M | $1.7M | $1.6M | $1.5M | $1.4M | $1.5M | $2.1M | $2.8M | $3.4M | $3.2M |
| SG&A | $178.4M | $164.0M | $167.1M | $153.1M | $154.1M | $131.3M | $128.7M | $138.4M | $129.6M | $120.3M |
| Operating income | $24.7M | $20.1M | $18.7M | $16.3M | $34.7M | $21.5M | $16.1M | $5.4M | $1.4M | $10.0M |
| Interest expense | $98.0K | $146.0K | $69.0K | $249.0K | $250.0K | $102.0K | $43.0K | $387.0K | $289.0K | $16.0K |
| Pre-tax income | $29.8M | $18.4M | $20.2M | $15.2M | $31.8M | $22.8M | $15.6M | $3.2M | $3.2M | $9.3M |
| Income tax | $9.4M | $10.5M | $3.8M | $14.7M | $1.6M | $137.0K | $8.7M | $4.4M | $17.0M | $8.6M |
| Net income | $19.5M | $7.7M | $15.1M | -$390.0K | $30.2M | $23.0M | $6.9M | -$1.2M | -$13.8M | $675.0K |
| EPS, basic | 1.08 | 0.41 | 0.79 | -0.02 | 1.45 | 1.09 | 0.35 | -0.04 | -0.69 | 0.11 |
| EPS, diluted | 1.06 | 0.40 | 0.77 | -0.02 | 1.42 | 1.07 | 0.34 | -0.04 | -0.69 | 0.11 |
| Shares, diluted (wtd. avg.) | $18.5M | $19.1M | $19.5M | $19.3M | $20.3M | $20.0M | $19.7M | $19.1M | $18.9M | $19.1M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $93.9M | $84.7M | $82.4M | $60.0M | $86.2M | $92.1M | $53.6M | $50.6M | $42.9M | $32.3M |
| Receivables | $8.6M | $9.5M | $8.8M | $14.1M | $8.9M | $7.4M | $7.3M | $7.8M | $8.9M | $7.7M |
| Inventory | $68.3M | $59.4M | $66.9M | $67.9M | $60.9M | $47.7M | $46.7M | $42.0M | $44.0M | $47.6M |
| Total current assets | $178.8M | $160.6M | $165.8M | $149.5M | $164.7M | $154.1M | $112.7M | $106.8M | $102.5M | $94.5M |
| Property, plant and equipment | $32.9M | $39.6M | $45.0M | $46.2M | $50.9M | $54.4M | $59.5M | $64.1M | $69.1M | $73.3M |
| Other intangibles | — | — | — | — | — | — | $567.0K | $618.0K | $709.0K | $976.0K |
| Total assets | $261.1M | $240.9M | $249.8M | $229.8M | $258.9M | $249.5M | $213.1M | $193.0M | $195.2M | $205.6M |
| Accounts payable | $8.0M | $8.9M | $7.9M | $6.3M | $9.7M | $6.5M | $4.4M | $5.2M | $4.2M | $5.3M |
| Short-term debt | — | — | $0 | $1.2M | $1.2M | $1.3M | $0 | — | $0 | $9.9M |
| Total current liabilities | $78.5M | $65.7M | $76.8M | $65.6M | $76.7M | $69.7M | $57.9M | $66.7M | $53.7M | $63.0M |
| Long-term debt | — | — | — | $0 | $1.2M | $2.4M | $0 | — | — | — |
| Total liabilities | $99.6M | $79.9M | $90.2M | $82.7M | $97.5M | $92.3M | $83.6M | $72.4M | $75.5M | $73.2M |
| Retained earnings | $76.9M | $57.4M | $49.7M | $34.6M | $35.0M | $26.0M | $4.7M | -$2.1M | -$2.1M | $12.7M |
| Total equity | $161.6M | $161.0M | $159.5M | $147.0M | $161.4M | $157.2M | $129.4M | $120.6M | $119.7M | $132.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $35.3M | $25.3M | $41.2M | $710.0K | $34.6M | $37.7M | $8.5M | $21.8M | $10.5M | $3.4M |
| Depreciation and amortisation | $13.8M | $14.2M | $11.8M | $11.0M | $11.2M | $10.7M | $10.6M | $9.8M | $8.6M | $4.8M |
| Stock-based compensation | $5.8M | $4.8M | $4.9M | $2.9M | $3.7M | $3.8M | $2.1M | $2.2M | $2.2M | $3.2M |
| Capital expenditure | $6.5M | $11.0M | $10.5M | $7.6M | $6.7M | $4.9M | $5.1M | $4.8M | $5.5M | $11.0M |
| Investing cash flow | -$6.5M | -$11.0M | -$10.5M | -$7.6M | -$6.6M | -$4.9M | -$5.1M | $211.0K | -$3.2M | -$11.5M |
| Financing cash flow | -$23.8M | -$9.9M | -$8.0M | -$16.2M | -$31.7M | $3.9M | -$63.0K | -$12.2M | $1.6M | -$286.0K |
| Dividends paid | — | — | — | $0 | $19.9M | $0 | — | $0 | $1.8M | $7.5M |
| Buybacks | $16.3M | $8.9M | $6.4M | $13.6M | $7.4M | $0 | — | — | $0 | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-016540.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |